The Urgent Need for a Sickle Cell Vaccine

In partnership with

Sickle cell disease (SCD) is a severe, inherited blood disorder that affects millions worldwide, particularly people of African, Mediterranean, Middle Eastern, and South Asian descent. The condition stems from a genetic mutation that causes red blood cells to adopt a rigid, crescent or "sickle" shape, rather than their normal, flexible, disc-like form. These misshapen cells can clump together and block small blood vessels, leading to episodes of intense pain, known as vaso-occlusive crises, along with complications such as organ damage, stroke, and increased risk of early death.

Find out why 1M+ professionals read Superhuman AI daily.

In 2 years you will be working for AI

Or an AI will be working for you

Here's how you can future-proof yourself:

1. Join the Superhuman AI newsletter – read by 1M+ people at top companies

2. Master AI tools, tutorials, and news in just 3 minutes a day

3. Become 10X more productive using AI

Join 1,000,000+ pros at companies like Google, Meta, and Amazon that are using AI to get ahead.

Sign up and start learning AI

Despite the global burden of the disease, treatment options remain limited—and recent setbacks in drug development only underscore the critical need for long-term preventive solutions, such as a vaccine.

One of the latest disappointments came from Pfizer, which recently announced that its experimental therapy, inclacumab, did not demonstrate significant benefits in reducing vaso-occlusive crises compared to a placebo in a large Phase 3 clinical trial. The study included 241 participants aged 16 and older who had experienced multiple pain crises in the previous year. The therapy, delivered every 12 weeks via infusion, aimed to reduce these painful episodes by targeting a specific protein involved in the disease process.

Inclacumab is an antibody designed to block P-selectin, a molecule found on the surface of activated platelets. While P-selectin plays a normal role in clotting, it also contributes to the cell clumping and inflammation that drive vaso-occlusive crises in sickle cell disease. The goal was to disrupt this harmful process—but the trial failed to show a statistically meaningful improvement.

This isn’t Pfizer’s first challenge in tackling SCD. Last year, the company pulled another sickle cell drug, Oxbryta, from the market after follow-up studies revealed higher rates of pain crises and deaths among those taking the drug. Both the trial and real-world data raised serious concerns, despite the drug’s earlier approval based on its ability to reduce hemoglobin polymerization—a key step in the sickling of red blood cells.

The setbacks highlight a difficult truth: while advances have been made, treating sickle cell disease remains a significant challenge. Pfizer's ongoing pipeline includes another drug, osivelotor, a next-generation version of Oxbryta, though that program is currently paused due to regulatory concerns.

What these repeated hurdles make clear is the pressing need for more effective, safer, and ideally preventive approaches. A vaccine could be transformative—targeting the root of the disease before complications ever begin, rather than chasing symptoms after they arise. While no such vaccine currently exists, these disappointments should serve as a rallying call for greater investment in sickle cell research, not only for treatments but for truly preventative strategies.

The sickle cell community deserves solutions that don’t just manage the disease—they deserve breakthroughs that eliminate the need for chronic treatment altogether.